Table 2.
Rank | KEGG Pathway | Number of genes (%) | P* |
---|---|---|---|
1 | Pathways in cancer | 21 (2.9) | 5.4E2 |
2 | Regulation of actin cytoskeleton | 19 (2.6) | 3.4E3 |
3 | Focal adhesion | 17 (2.4) | 9.1E3 |
4 | Ubiquitin mediated proteolysis | 15 (2.1) | 1.6E3 |
5 | Chemokine signaling pathway | 14 (1.9) | 4.7E2 |
6 | Endocytosis | 13 (1.8) | 8.1E2 |
7 | Fc gamma Rmediated phagocytosis | 12 () | 1.8E3 |
8 | Chronic myeloid leukemia | 11 (1.7) | 9.9E4 |
9 | Insulin signaling pathway | 11 (1.5) | 5.4E2 |
10 | Wnt signaling pathway | 11 (1.5) | 9.8E2 |
11 | Pancreatic cancer | 10 (1.4) | 2.8E3 |
12 | Adherens junction | 10 (1.4) | 4.4E3 |
13 | Vascular smooth muscle contraction | 9 (1.2) | 9.4E2 |
14 | Colorectal cancer | 9 (1.2) | 2.3E2 |
15 | TGFbeta signaling pathway | 9 (1.2) | 2.8E2 |
16 | Oocyte meiosis | 9 (1.2) | 8.7E2 |
17 | Longterm potentiation | 8 (1.1) | 2.2E2 |
18 | Phosphatidylinositol signaling system | 8 (1.1) | 3.4E2 |
19 | Endometrial cancer | 7 (1) | 2.0E2 |
20 | Acute myeloid leukemia | 7 (1) | 3.3E2 |
21 | Melanoma | 7 (1) | 7.4E2 |
22 | B cell receptor signaling pathway | 7 (1) | 9.1E2 |
23 | VEGF signaling pathway | 7 (1) | 9.1E2 |
24 | Nonsmall cell lung cancer | 6 (0.8) | 7.3E2 |
25 | Dorsoventral axis formation | 4 (0.6) | 8.4E2 |
* The threshold of EASE score, a modified Fisher Exact P-value, for gene-enrichment analysis